The global smoking cessation and nicotine de-addiction market size is expected to reach USD 50.90 billion by 2030, growing at a CAGR of 10.4% from 2024 to 2030, according to a report by Grand View Research, Inc. The base of population addicted to smoking is rapidly increasing across the globe. This population subset majorly includes teenagers and the working population. Smoking-related mortality is very high. The increasing desire to quit smoking and the numerous health complications associated with smoking serve as strong incentives for companies to introduce novel smoking cessation products, such as Revolymer, which has introduced the next generation nicotine gums to help smokers quit smoking. The launch of these improved and innovative nicotine replacement therapy products is to serve as a high impact rendering driver for the growth of the smoking cessation and nicotine de-addiction market.
The growing incidence of target diseases such as chronic obstructive pulmonary disease (COPD), asthma, cardiac diseases, and lung cancer, and the increasing awareness pertaining to the hazardous side-effects of smoking are the factors expected to promote market expansion. Educational institutions remain active in organizing various campaigns and programs to spread information about the harmful effects and consequences of smoking so as to increase young population awareness.
Request a free sample copy or view report summary: Smoking Cessation And Nicotine De-addiction Market Report
Nicotine Replacement Therapy (NRT) dominated the smoking cessation and de-nicotine addiction product market in 2023. Majorly used NRT products include nicotine chewing gums and the transdermal patches. Increased availability and the introduction of the ingestible nicotine products with different flavors are the factors responsible for its large market share.
The e-cigarette segment is anticipated to grow at a CAGR of 8.48% over the forecast period. The major factors responsible for the growth of the E-cigarette market include the introduction of second and third generation e-cigarettes, the availability of various flavored products, the presence of numerous vendors operating and selling e-cigarettes under different brand names.
North America dominated the smoking cessation and nicotine de-addiction market with a market share of 40.3% in 2023.
Asia Pacific is the fastest growing market. The registration of nicotine de-addiction products and e-cigarettes as well as the strengthening of the company distribution channels in countries, such as China, India, and Australia are expected to support the growth over the forecast period.
The market players are making slow but steady progress in the e-cigarette market by focusing on the development, commercialization, and distribution of the FDA approved nicotine products. For instance, in 2014, Victory Electronic Cigarettes Corporation acquired Ten Motives Ltd. with an aim to expand their distribution channels and attain wider market coverage.
Grand View Research has segmented the global smoking cessation and nicotine de-addiction market report based on type, form, distribution channel, and region:
Smoking Cessation And Nicotine De-addiction Type Outlook (Revenue, USD Million, 2018 - 2030)
Nicotine Replacement Therapy
Nicotine Lozenges
Nicotine Gums
Nicotine Sprays
Nicotine Inhalers
Drug Therapy
E-cigarettes
Smoking Cessation And Nicotine De-addiction Form Outlook (Revenue, USD Million, 2018 - 2030)
Gum
Inhaler
Tablet
Others
Smoking Cessation And Nicotine De-addiction Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Online
Drug stores and Retail Pharmacies
Smoking Cessation And Nicotine De-addiction Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Smoking Cessation And Nicotine De-addiction Market
Rusan Pharma Ltd
Dr. Reddy’s Laboratories Ltd
Imperial Brands Plc
Zydus Group.
British American Tobacco Plc
Perrigo Company Plc
Johnson and Johnson Inc
NJOY, LLC
Cipla Ltd
GlaxoSmithKline Plc.
"The quality of research they have done for us has been excellent..."